Commercialization of Medical Artificial Intelligence Technologies: Challenges and Opportunities
Artificial intelligence (AI) is rapidly transforming healthcare, particularly through innovations in medical imaging and diagnostic support. A recently published article in npj Digital Medicine by Ben Li, Dylan Powell, and Regent Lee (2025) sheds light on the commercialization landscape of medical AI technologies, focusing on both the challenges and the emerging opportunities in this evolving field.
AI in Healthcare: Transforming Diagnosis and Treatment
Vascular diseases, including carotid artery disease, aortic aneurysms, and peripheral artery disease, affect more than 200 million people worldwide. These conditions often lead to severe outcomes such as stroke, aneurysm rupture, and limb loss. Diagnosis and treatment typically rely on medical imaging methods such as ultrasound, computed tomography (CT), and fluoroscopy. AI-guided imaging tools have begun to enhance these diagnostic processes, offering new possibilities for real-time image analysis and improved clinical decision-making.
One notable advancement highlighted in the article is the development of an AI algorithm by Chiu and colleagues (2024) aimed at diagnosing abdominal aortic aneurysms (AAA). This condition, frequently underdetected, carries a mortality rate of up to 80% when ruptured. The AI tool supports nurses without ultrasound training to perform AAA screening with accuracy comparable to that of ultrasound-trained physicians. By guiding probe placement and automatically measuring aorta diameter, the algorithm enables efficient screening that could be especially impactful in underserved areas experiencing shortages of imaging specialists.
Path from Innovation to Clinical Impact
Despite promising technological progress, integrating AI tools into routine clinical practice remains complex. The article discusses that commercializing medical AI involves more than demonstrating algorithmic performance; it requires navigating a multifaceted pathway including funding acquisition, regulatory compliance, safety assurance, health technology assessment, reimbursement strategies, and alignment with clinical guidelines.
A key case study featured is a U.S.-based AI company founded in 2016 that initially focused on neurological care but has expanded into cardiovascular and oncological applications. This company has successfully developed multiple FDA-cleared AI products analyzing various imaging modalities like CT scans, electrocardiograms, and echocardiograms. Their solutions assist physicians in diagnosing conditions such as ischemic stroke, cerebral aneurysm, pulmonary embolism, and abdominal aortic aneurysm.
The company’s success is attributed to a multidisciplinary approach combining clinical expertise and engineering, early integration of regulatory and quality management standards—including ISO certifications—and strong collaboration with academic partners. Moreover, conducting health technology assessments demonstrated significant potential cost savings, underpinning investor confidence and facilitating the acquisition of over $290 million in funding. Their engagement with the U.S. Centers for Medicare and Medicaid Services established new billing codes supporting reimbursement for AI-based diagnostics, achieving clinical guideline integration and aiding financial viability.
Overcoming Barriers to Commercialization
Despite the promise, many AI products struggle to make the leap from academic research to scaled clinical deployment. Funding gaps often occur after initial algorithm development, particularly as public grants taper off before commercialization phases. Private investment plays a vital role but typically demands robust evidence linking AI tools to tangible health system impacts and revenue generation.
Regulatory approval processes, while increasingly successful—over 1,000 AI medical devices have received FDA clearance—remain rigorous and resource-intensive. Additional challenges include navigating international regulatory environments, ensuring data privacy and cyber-security, and achieving clinician acceptance through demonstration of clinical utility and ease of use.
Implementation barriers also involve integration with existing health IT infrastructure, training healthcare staff in new workflows, and securing reimbursement frameworks that incentivize adoption. As reimbursement pathways vary regionally and can take years to establish, persistence, mentorship, and cross-sector collaboration emerge as critical enablers for success.
Future Outlook
The commercialization trajectory of medical AI demands a strategic blend of innovation, regulation, clinical validation, and business acumen. The example of the AAA screening algorithm and the experience of established AI companies provide valuable lessons and pathways for emerging technologies seeking to address pressing clinical needs.
As global healthcare systems increasingly adopt AI solutions, overcoming financial, regulatory, and operational hurdles will be essential to harness AI’s full potential to improve patient outcomes and health system efficiency. Continued multidisciplinary collaboration among researchers, clinicians, industry players, regulators, and payers will be key to transforming promising AI algorithms from research prototypes into routine clinical tools that benefit patients worldwide.
—
Reference:
Li B, Powell D, Lee R. Commercialization of medical artificial intelligence technologies: challenges and opportunities. npj Digital Medicine. 2025;8:454. https://doi.org/10.1038/s41746-025-00454-x
